Infigratinib

CHEMBL1852688 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

560.5 g/mol

LogP

4.7

Phase

4

This oral fibroblast growth factor receptor (FGFR) inhibitor is used to treat FGFR2 fusion-positive, locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer). It works by blocking FGFR2 signaling that drives tumor cell proliferation in patients with specific genetic alterations. Hyperphosphatemia (elevated blood phosphate) is a common side effect due to FGFR1 inhibition.

Masse moléculaire

560,5000 g/mol

LogP

4,70

TPSA

95,10 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Melanoma Pancreatic Cancer Bladder Cancer Breast Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1

InChI

InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)

Molecular Formula

C26H31Cl2N7O3

HBD / HBA

2 / 8

Liaisons Rotatives

8

Atomes Lourds

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This oral fibroblast growth factor receptor (FGFR) inhibitor is used to treat FGFR2 fusion-positive, locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer). It works by blocking FGFR2 signaling that drives tumor cell proliferation in patients with specific genetic alterations. Hyperphosphatemia (elevated blood phosphate) is a common side effect due to FGFR1 inhibition.

Yes, Infigratinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1852688. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 53235510. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Infigratinib sur PillFYI

Structure

Données Clés

Formule: C26H31Cl2N7O3

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.